| scholarly article | Q13442814 |
| P50 | author | Mark Holodniy | Q37367057 |
| Lauren E. Cipriano | Q38544105 | ||
| Jeremy Goldhaber-Fiebert | Q65967291 | ||
| P2093 | author name string | Shan Liu | |
| P2860 | cites work | Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement | Q22305313 |
| Quality-of-life weights for the US population: self-reported health status and priority health conditions, by demographic characteristics | Q23915053 | ||
| Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B | Q28251578 | ||
| Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus | Q28279955 | ||
| Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
| Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 | ||
| The impact of diagnosis of hepatitis C virus on quality of life. | Q33759461 | ||
| The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings | Q33834958 | ||
| Appropriateness of liver biopsy | Q33963882 | ||
| Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients | Q34098870 | ||
| Trends in medical spending by age, 1963-2000. | Q34342102 | ||
| Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression | Q34787367 | ||
| Empirically calibrated model of hepatitis C virus infection in the United States | Q34948964 | ||
| Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force | Q35692299 | ||
| Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. | Q35768976 | ||
| All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population | Q35974996 | ||
| Cost-effectiveness and population outcomes of general population screening for hepatitis C. | Q36115516 | ||
| Preference-Based EQ-5D index scores for chronic conditions in the United States | Q36541277 | ||
| New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis | Q36652084 | ||
| Comparing the costs of HIV screening strategies and technologies in health-care settings | Q36935852 | ||
| Health-state utilities in liver disease: a systematic review. | Q37142994 | ||
| Demographics of a large cohort of urban chronic hepatitis C patients | Q37278212 | ||
| Burden of illness of hepatitis C from a managed care organization perspective | Q40510825 | ||
| Predictive markers for hepatitis C antibody ELISA specificity in Australian blood donors | Q42980839 | ||
| Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection | Q42989510 | ||
| A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. | Q43035164 | ||
| Outcome of screening for hepatitis C virus infection based on risk factors | Q43040992 | ||
| Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. | Q43046858 | ||
| Economic model of a birth cohort screening program for hepatitis C virus | Q43047944 | ||
| Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population | Q43943787 | ||
| Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population | Q44324155 | ||
| Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. | Q44917702 | ||
| The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. | Q44979610 | ||
| Health values of patients with chronic hepatitis C infection | Q45158760 | ||
| Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention | Q45355364 | ||
| Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. | Q45734380 | ||
| Screening for hepatitis C virus in a health maintenance organization | Q45742048 | ||
| Diagnostic tests for hepatitis C | Q73717379 | ||
| Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis. | Q50556008 | ||
| Treatment rates in patients with chronic hepatitis C after liver biopsy. | Q50575063 | ||
| Health-state utilities and quality of life in hepatitis C patients. | Q50583400 | ||
| A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. | Q52010912 | ||
| Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. | Q52249518 | ||
| Health-State Utilities and Quality of Life in Hepatitis C Patients | Q57696013 | ||
| Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006 | Q64128835 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | risk factor | Q1475848 |
| hepatitis C | Q154869 | ||
| cost-effectiveness analysis | Q1754768 | ||
| chronic hepatitis C | Q55779873 | ||
| chronic hepatitis | Q62019625 | ||
| birth cohort | Q64532946 | ||
| P304 | page(s) | e58975 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States | |
| P478 | volume | 8 |
| Q59353097 | A Multi-Fidelity Rollout Algorithm for Dynamic Resource Allocation in Population Disease Management |
| Q36748876 | Age-period-cohort analysis of infectious disease mortality in urban-rural China, 1990-2010. |
| Q42048758 | Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease |
| Q42203865 | Birth year distribution in reported hepatitis C cases in Switzerland. |
| Q35935659 | Comparison of Rapid Point-of-Care Tests for Detection of Antibodies to Hepatitis C Virus |
| Q26774500 | Cost-Effectiveness of HBV and HCV Screening Strategies--A Systematic Review of Existing Modelling Techniques |
| Q35619161 | Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States |
| Q35058571 | Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence |
| Q34735072 | Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs |
| Q35088460 | Cost-effectiveness of screening for hepatitis C in Canada |
| Q37251861 | Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations |
| Q42227512 | Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. |
| Q46983780 | Economic evaluation of HCV testing approaches in low and middle income countries |
| Q87645999 | Economic evaluation of pooled solvent/detergent treated plasma versus single donor fresh-frozen plasma in patients receiving plasma transfusions in the United States |
| Q26998567 | Economic evaluation of screening programs for hepatitis C virus infection: evidence from literature |
| Q91610876 | Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies |
| Q54593526 | Hepatitis C Screening of the "Birth Cohort" (Born 1945-1965) and Younger Inmates of New York City Jails. |
| Q57167190 | Hepatitis C in Lebanon: the burden of the disease and the value of comprehensive screening and treatment |
| Q59418647 | Impact of race/ethnicity and gender on HCV screening and prevalence among U.S. veterans in Department of Veterans Affairs Care |
| Q40118666 | In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered |
| Q41256468 | Lack of health insurance limits the benefits of hepatitis C virus screening: insights from the National Health and Nutrition Examination Hepatitis C follow-up study |
| Q59353323 | Optimal Information Collection Policies in a Markov Decision Process Framework |
| Q92052156 | Optimizing Implementation of Hepatitis C Birth-Cohort Screening and Treatment Strategies: Model-Based Projections |
| Q38983274 | Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment |
| Q57145115 | Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence |
| Q40049914 | Population-level intervention and information collection in dynamic healthcare policy. |
| Q36862066 | Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons |
| Q91620187 | Screening a nation for hepatitis C virus elimination: a cross-sectional study on prevalence of hepatitis C and associated risk factors in the Rwandan general population |
| Q47603693 | Should we treat acute hepatitis C? A decision and cost-effectiveness analysis |
| Q35037688 | Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis |
| Q40168920 | The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics |
| Q41207230 | The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus |
| Q40524477 | Uptake of hepatitis C screening, characteristics of patients tested, and intervention costs in the BEST-C study |
| Q33719771 | Why equal treatment is not always equitable: the impact of existing ethnic health inequalities in cost-effectiveness modeling |
Search more.